Skip to Content
Header image


The burden of diabetes is enormous and escalating at an alarming rate. Nearly 26 million Americans have the disease, including over 10% of the total adult population and over 25% of the population aged 65 years and older. Halloran has numerous consultants with a wealth of experience in both Type 1 and Type 2 diabetes in all phases of clinical trials globally. In the last two years, Halloran has worked on a variety of therapies being developed for T1D and T2D including monoclonal antibodies, microbiome derived therapies, oligo derived therapies and small molecule.